openPR Logo
Press release

Infliximab Market - Analysis and Forecast 2018 - 2026 Explored in Latest Research

06-11-2018 01:28 PM CET | Health & Medicine

Press release from: Transparency Market Research

Infliximab Market - Analysis and Forecast 2018 - 2026 Explored

Biosimilars are biological products that are similar to FDA-approved drug known as branded drug. Biosimilars are drugs licensed by the European Medicines Agency (EMA) and the U.S. FDA. These do not have significant differences from the reference products in terms of purity, effectiveness, and safety. Biosimilar drugs can only be permitted for conditions and indications that have been formerly accepted for the reference product by government regulatory agencies and organizations, when the original products patents expires. Compared to generic drugs, biosimilars show more molecular complexity. These are also quite sensitive to modifications in the manufacturing process.

Infliximab (Remicade) is a monoclonal antibody first manufactured by Janssen Biotech, Inc. in collaboration with Merck & Co. The U.S. Food and Drug Administration (FDA) first approved it in 1998. It is used in the treatment of active ulcerative colitis, rheumatoid arthritis, active and spinal psoriatic arthritis, Crohn’s disease (inflammatory bowel disease) in both pediatric and adult patients, and plaque psoriasis. Infliximab binds to chemical messenger tumor necrosis factor (TNF-α). It is one of the important part of autoimmune reaction. TNF-α stimulates the overall messenger cascade. Infliximab seems to act by binding to the receptor in the cell.

Obtain Report Details @ https://www.transparencymarketresearch.com/infliximab-market.html

The global infliximab market is projected to grow at a rapid pace in the next few years. Increase in incidence of hereditary and autoimmune diseases such as plaque psoriasis and rheumatoid arthritis drive the global market. The number of people suffering from Crohn’s disease and ulcerative colitis (UC) has increased in various regions in the past few years. All the inflammatory bowel diseases (IBD) are associated with considerable morbidity cases with substantial use of health care resources. Early patent expiry, discounted pricing on branded drugs, and quick response time due to intravenous mode of administration propel the market.

Additionally, entry of biosimilars into the market has the ability to provide significant financial relief to the current health care systems. However, side effects of the drug treatment such as histoplasmosis (fungal infection), tuberculosis (TB), bacterial sepsis, and others restrain the global infliximab market. Hence, manufacturers of the drug have been mandated to include warnings to alert both patients and health care professionals. Additionally, lack of FDA-approved facilities, especially in developing countries, to manufacture the drug are the factors expected to restrain the market.

Download Report Brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=43640

The global infliximab market can be segmented based on product and application. In terms of product, the global infliximab market can be bifurcated into biologics and biosimilars. Based on application, the global infliximab market can be divided into rheumatoid arthritis, ankylosing spondylitis, plaque psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis.

Geographically, the global infliximab market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America and Europe are projected to dominate the market, followed by Asia Pacific and Latin America. Dominance of North America and Europe is attributed to launch of biosimilars after patent expiry.

The market in Asia Pacific is anticipated to grow at a rapid pace in the next few years. This is due to presence of rapidly developing economies such as China and India, increase in awareness about health and hygiene, enhanced health care infrastructure, and unexploited market as increase in geriatric population that lacks adequate diagnostic & treatment solutions. Additionally, rise in government support for the manufacture of biosimilars drugs and increase in awareness and adoption of biosimilars is anticipated to drive the global infliximab market.

Enquiry for Discount on this Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=43640

Key players in the global infliximab market are Merck & Co., Celltrion, Inc., Alvogen, Janssen Biotech, Inc., NAPP Pharmaceuticals, Nippon Kayaku, and Pfizer, Inc. (AC. Hospira), among others.

About Us

Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Contact Us

Transparency Market Research
State Tower,
90 State Street, Suite 700
Albany, NY 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Infliximab Market - Analysis and Forecast 2018 - 2026 Explored in Latest Research here

News-ID: 1077352 • Views: 379

More Releases from Transparency Market Research

Nanotechnology Drug Delivery market is estimated to attain a valuation of US$ 14 …
The global Nanotechnology Drug Delivery market is estimated to attain a valuation of US$ 142.8 Bn by the end of 2028, states a study by Transparency Market Research (TMR). Besides, the report notes that the market is prognosticated to expand at a CAGR of 7.9% during the forecast period, 2021 to 2028. The key objective of the TMR report is to offer a complete assessment of the global market including
Endoscopy Devices market is estimated to attain a valuation of US$ 42.8 Bn by th …
The global Endoscopy Devices market is estimated to attain a valuation of US$ 42.8 Bn by the end of 2028, states a study by Transparency Market Research (TMR). Besides, the report notes that the market is prognosticated to expand at a CAGR of 3.8% during the forecast period, 2021 to 2028. The key objective of the TMR report is to offer a complete assessment of the global market including major
Surgical Microscopes market is estimated to attain a valuation of US$ 1.7 Bn by …
The global Surgical Microscopes market is estimated to attain a valuation of US$ 1.7 Bn by the end of 2031, states a study by Transparency Market Research (TMR). Besides, the report notes that the market is prognosticated to expand at a CAGR of 8.3% during the forecast period, 2022-2031. The key objective of the TMR report is to offer a complete assessment of the global market including major leading stakeholders of
Personal Mobility Devices market is estimated to attain a valuation of US$ 20.5 …
The global Personal Mobility Devices market is estimated to attain a valuation of US$ 20.5 Bn by the end of 2031, states a study by Transparency Market Research (TMR). Besides, the report notes that the market is prognosticated to expand at a CAGR of 7.1% during the forecast period, 2022-2031. The key objective of the TMR report is to offer a complete assessment of the global market including major leading stakeholders

All 5 Releases


More Releases for Infliximab

Infliximab Biosimilar Insight, 2022 | DelveInsight
DelveInsight's, "Infliximab Biosimilar Insight, 2022" report provides comprehensive insights about 35+ companies and 45+ marketed and pipeline drugs in Infliximab Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Interested to know more about the functioning of
Global Infliximab and Biosimilar Market Analysis during 2022-2028
The global infliximab and biosimilar market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). The infliximab is a monoclonal anti-tumor necrosis antibody used to treat certain types of arthritis (rheumatoid arthritis, psoriatic arthritis), certain bowel diseases (Crohn's disease and ulcerative colitis), and serious skin disease (chronic plaque psoriasis). Biosimilar is a medicine that is close in structure and function to a biological drug. The rise
Infliximab and Biosimilar Market 2021 | Detailed Report
Infliximab and Biosimilar Market Forecasts report provided to identify significant trends, drivers, influence factors in global and regions, agreements, new product launches and acquisitions, Analysis, market drivers, opportunities and challenges, risks in the market, cost and forecasts to 2027. Get Free Sample PDF (including full TOC, Tables and Figures) of Infliximab and Biosimilar Market @ https://www.reportsnreports.com/contacts/requestsample.aspx?name=5048518 The report provides a comprehensive analysis of company profiles listed below: - Janssen Biotech - Merck and
Adalimumab, Infliximab And Etanercept Biosimilars Market 2021 Segmentation, Futu …
New year, new updates! Our reports have been revised for market size, forecasts, and strategies to take on 2021 after the COVID-19 impact: https://www.thebusinessresearchcompany.com/global-market-reports The global adalimumab, infliximab and etanercept biosimilars market is expected to grow from $2.21 billion in 2020 to $3.02 billion in 2021 at a compound annual growth rate (CAGR) of 36.7%. The growth is mainly due to the companies resuming their operations and adapting to the new
Infliximab Market Report Analysis With Industry Share Published by Leading Resea …
Biosimilars are biological products that are similar to FDA-approved drug known as branded drug. Biosimilars are drugs licensed by the European Medicines Agency (EMA) and the U.S. FDA. These do not have significant differences from the reference products in terms of purity, effectiveness, and safety. Biosimilar drugs can only be permitted for conditions and indications that have been formerly accepted for the reference product by government regulatory agencies and organizations,
Impact of COVID-19 on Infliximab Market
Biosimilars are biological products that are similar to FDA-approved drug known as branded drug. Biosimilars are drugs licensed by the European Medicines Agency (EMA) and the U.S. FDA. These do not have significant differences from the reference products in terms of purity, effectiveness, and safety. Biosimilar drugs can only be permitted for conditions and indications that have been formerly accepted for the reference product by government regulatory agencies and organizations,